This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Abbott (ABT) Expands in Electrophysiology With New FDA Nod
by Zacks Equity Research
Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.
3 Reasons to Hold Inspire Medical (INSP) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inspire Medical (INSP) on the back of its product innovations.
BD's (BDX) Latest Product Launch to Boost Research Outcome
by Zacks Equity Research
BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting and allow researchers to answer complex biological questions.
Hologic (HOLX) Gets FDA Nod for Multiplexed Respiratory Test
by Zacks Equity Research
Hologic's (HOLX) Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is done using the fully-automated, high-throughput Panther Fusion system.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.
Here's Why You Should Retain Humana (HUM) in Your Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth, attributable to a growing customer base, numerous contract wins and solid cash-generating abilities.
Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval
by Zacks Equity Research
Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.
What's in the Cards for Medtronic (MDT) in Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) is likely to have prioritized its R&D investments, which might get reflected in the fiscal Q4 results.
STERIS (STE) Continues to Face Dull Dental Sales, Margin Woes
by Zacks Equity Research
STERIS (STE) competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Veeva Systems' (VEEV) New Launch to Improve Patient Outcomes
by Zacks Equity Research
Veeva Systems' (VEEV) new offering is expected to facilitate effective engagement with customers and KOLs for improved patient journeys.
Edwards Lifesciences' (EW) TAVR Study Outcome Favorable
by Zacks Equity Research
Edwards Lifesciences' (EW) latest findings of the study confirm the value of the Edwards Benchmark programme for standardizing clinical pathways for patients undergoing TAVR in Europe.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) on its strong execution of strategies, disciplined cost management and revenue timing.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
BD's (BDX) New FDA Approval to Improve MRSA Diagnostics
by Zacks Equity Research
BD's (BDX) receipt of the latest FDA approval is likely to improve laboratory workflow.
Medtronic's (MDT) Global Market Share Strong, FX Headwind Stays
by Zacks Equity Research
Within cardiac rhythm management, Medtronic's (MDT) pacing business continues to outperform the market, banking on strong global growth of its Micra leadless pacemaker family.
LabCorp (LH) Expands Laboratory Relationship With New Pact
by Zacks Equity Research
LabCorp's (LH) recent partnership will expand healthcare access, offer advanced diagnostic tools and guarantee that both patients and doctors can afford the treatments they get.
NextGen (NXGN) Q4 Earnings Top Estimates, Revenues Surge Y/Y
by Zacks Equity Research
NextGen's (NXGN) fourth-quarter fiscal 2023 results reflect strength in both its revenue sources.
3 Reasons to Retain Masimo (MASI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Alcon (ALC) Vision Care Sales Robust, Margin Pressure Persists
by Zacks Equity Research
For Alcon (ALC), in terms of end market, Surgical global cataract procedure growth varies significantly by region.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod
by Zacks Equity Research
Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) on strategic partnerships and upbeat guidance.
Shockwave Medical (SWAV) Launches IVL Catheter in Select Markets
by Zacks Equity Research
Shockwave Medical's (SWAV) latest commercial availability and the patient enrollment in its study are expected to serve a wider patient pool.